Lipodystrophy is common in children from three European cohorts

HIV Treat Bull - 2009 Nov/Dec;10(11/12): 08

Simon Collins, HIV i-Base

Researchers from 14 sites in Belgium, Poland and Italy reported the prevalence of lipodystrophy in a cohort of 468 children and adolescents (92% infected at birth). Data collected included demographic and clinical history and used standardised assessment to determine fat loss or accumulation in the face, limbs, buttocks, breasts, neck and trunk.

The cohort was evenly split by gender, with median age 13.5 years (IQR 9.9-17.0). Tanner puberty stage included 28 stage I and 34% stage V. In this group, 73% were white and 22% Black African. HIV treatment was used by 95% of the cohort for a median 8.8 years, with 62% having viral load suppressed <50 copies/mL. The median CD4% was 31% (IQR 24-38) and just over 300 children were currently asymptomatic. Assessment of symptoms was by clinician-completed questionnaire. Over 40% of children had at least one lipodystrophy symptom: 15% had just fat loss, 13% just fat accumulation (mostly trunk) and 13% had both symptoms. This group included 14 cases of severe fat accumulation and 11 cases of both severe fat loss and fat accumulation.

In multivariate analysis, after controlling for duration of treatment, maternal lipodystrophy, maximal CDC status, and having ever used d4T, indinavir, d-drugs and efavirenz, significant associations were found for d4T use (AOR 4.23; 2.02, 8.85), efavirenz use (AOR=2.72; 1.36, 5.46), indinavir use (AOR 3.23) and clinical stage (AOR 3.30; 1.28, 8.02) and either fat loss or fat accumulation. Even stronger associations were found for children who had both symptoms.

Maternal lipodystrophy was also associated with an adjusted OR of 3.01 (1.78, 5.57) for any symptom and 4.75 (1.60, 14.20) for both symptoms.

Ref: Alam NM et al. Risk factors for body fat redistribution in a European cohort of HIV-infected children and adolescents. 11th Intl Workshop on Adverse Drug Reactions. 26-28 October 2009, Philadelphia. Poster abstract P-06. Antiviral therapy 2009; 14 Suppl 2: A27.

2009-11-10
IB2009-11-08

©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in November 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.